bluebird bio Announces Proposed Public Offering Of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that it has commenced an underwritten public offering of $150 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering.

Help employers find you! Check out all the jobs and post your resume.